A detailed history of Black Rock Inc. transactions in Personalis, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 3,280,721 shares of PSNL stock, worth $3.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,280,721
Previous 3,315,268 1.04%
Holding current value
$3.94 Million
Previous $6.96 Million 29.79%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.15 - $2.19 $39,729 - $75,657
-34,547 Reduced 1.04%
3,280,721 $4.89 Million
Q4 2023

Feb 13, 2024

SELL
$0.93 - $2.35 $13,587 - $34,333
-14,610 Reduced 0.44%
3,315,268 $6.96 Million
Q3 2023

Nov 13, 2023

SELL
$1.19 - $2.36 $77,407 - $153,513
-65,048 Reduced 1.92%
3,329,878 $4.03 Million
Q2 2023

Aug 11, 2023

SELL
$1.8 - $3.19 $28,600 - $50,685
-15,889 Reduced 0.47%
3,394,926 $6.38 Million
Q1 2023

May 12, 2023

SELL
$2.01 - $4.17 $297,676 - $617,568
-148,098 Reduced 4.16%
3,410,815 $9.41 Million
Q4 2022

Feb 13, 2023

BUY
$1.78 - $2.87 $486,595 - $784,566
273,368 Added 8.32%
3,558,913 $7.05 Million
Q3 2022

Nov 14, 2022

BUY
$3.04 - $5.32 $1.99 Million - $3.49 Million
656,235 Added 24.96%
3,285,545 $9.76 Million
Q2 2022

Aug 12, 2022

SELL
$3.27 - $8.76 $6.24 Million - $16.7 Million
-1,909,245 Reduced 42.07%
2,629,310 $9.07 Million
Q1 2022

May 12, 2022

BUY
$7.56 - $14.3 $1.13 Million - $2.13 Million
149,222 Added 3.4%
4,538,555 $37.2 Million
Q4 2021

Feb 10, 2022

BUY
$12.24 - $21.25 $10.5 Million - $18.2 Million
857,372 Added 24.27%
4,389,333 $62.6 Million
Q3 2021

Nov 09, 2021

BUY
$16.69 - $26.05 $767,673 - $1.2 Million
45,996 Added 1.32%
3,531,961 $68 Million
Q2 2021

Aug 11, 2021

BUY
$18.15 - $27.75 $63.3 Million - $96.7 Million
3,485,965 New
3,485,965 $88.2 Million

Others Institutions Holding PSNL

About Personalis, Inc.


  • Ticker PSNL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 45,918,400
  • Market Cap $55.1M
  • Description
  • Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or pla...
More about PSNL
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.